-
Fierce Biotech3 weeks ago
Novartis pays Synnovation $2B upfront for breast cancer program as rivals circle
Novartis has struck a deal to buy Synnovation Therapeutics’ pan-mutant‑selective PI3Kα inhibitor for $2 billion upfront, securing an asset that could defend its breast cancer franchise...
-
Fierce Biotech3 weeks ago
Gilead turns down chance to build on Assembly’s phase 1-stage HBV antiviral
Gilead has handed back a next-gen hepatitis B antiviral to Assembly Biosciences, while the two companies continue to partner on other assets.
-
Fierce Biotech3 weeks ago
Gilead turns down chance to build on Assembly’s phase 1-stage HBV antiviral
Gilead has handed back a next-gen hepatitis B antiviral to Assembly Biosciences, while the two companies continue to partner on other assets.
-
Fierce Biotech3 weeks ago
Verily banks $300M to accelerate AI road map, transitions to independent company
Verily raised a $300 million investment round to accelerate its work in artificial intelligence and precision health as it also moves out from under the corporate...
-
Fierce Biotech3 weeks ago
Chutes & Ladders—Eric Topol boards Flagship as advisor
Renowned cardiologist Eric Topol, M.D., is setting sail with Flagship Pioneering as an academic advisor for the firm’s Preemptive Health and Medicine Initiative. Topol is director...
-
Fierce Biotech3 weeks ago
Embecta to buy auto-injector maker Owen Mumford for $200M to diversify beyond insulin
Embecta has agreed to pay 100 million pounds sterling upfront for the company, or about $134.3 million, plus another 50 million pounds in sales milestones.
-
Fierce Biotech3 weeks ago
Genentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failure
Genentech has elected to stop a phase 2 trial of a RIPK1 inhibitor early and dump the asset after an analysis revealed the candidate was unlikely...
-
Fierce Biotech3 weeks ago
Pfizer adds to Seagen scrap heap with another early cancer candidate cull
About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, the company has trimmed another branch....
-
Fierce Biotech3 weeks ago
Syneos Health scoops up Chinese CRO to secure place in ‘rapidly growing market’
North Carolina-based contract research organization Syneos Health is making a play to capitalize on China’s rapidly ascendant biopharma industry. Syneos has acquired Chinese CRO Bestudy to...
-
Fierce Biotech3 weeks ago
Phage-focused BiomX resets after adverse events derail pipeline, considers pivot to defense sector
Phage-focused BiomX is undergoing a “strategic and financial reset” in efforts to improve the biotech’s financial position, mapping out a possible shift from therapeutics to the...
Terns rebuffed a higher bid before selling to Merck
